Assessment of a New Instrument for Detecting Preventable Adverse Drug Reactions

Drug Safety

Volumn 38, Issue 4, 2015, Pages 383-393

  Benkirane, Raja ^a,f   Soulaymani Bencheikh, Rachida ^b   Khattabi, Asmae ^c   Benabdallah, Ghita ^a   Alj, Loubna ^a   Sefiani, Houda ^a   Hedna, Khedidja ^d   Ouammi, Lahcen ^a   Olsson, Sten ^e   Pal, Shanti N ^e  

^a Moroccan Pharmacovigilance Centre   (Morocco)

^b MOHAMMED V UNIVERSITY   (Morocco)

^c Institut National d'Administration Sanitaire Morocco   (Morocco)

^d LINKÖPING UNIVERSITY   (Sweden)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

^f Centre Anti poison   (Morocco)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG SURVEILLANCE PROGRAM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMAN; INTERNATIONAL COOPERATION; ORGANIZATION AND MANAGEMENT; RISK FACTOR; WORLD HEALTH ORGANIZATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; INTERNATIONALITY; PHARMACOVIGILANCE; RISK FACTORS; WORLD HEALTH ORGANIZATION;

EID: 84939934707     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-014-0257-5     Document Type: Article

References (26)

1. Alj L, Touzani MDW, Benkirane R, Edwards IR, Soulaymani R. Detecting medication errors in pharmacovigilance database: capacities and limits. Int J Risk Saf Med. 2007;19(4):187–94.
2. Kunac DL, Tatley MV. Detecting medication errors in the New Zealand pharmacovigilance database: a retrospective analysis. Drug Saf. 2011;34(1):59–71.
3. Caduff-Janosa P. Medication errors in Switzerland: an analysis of the spontaneous adverse reactions reports received at the Swissmedic Pharmacovigilance Centre. Drug Saf. 2004;27:831–977.
4. Bencheikh RS, Benabdallah G. Medication errors: pharmacovigilance centres in detection and prevention. Br J Clin Pharmacol. 2009;67(6):687–90.
5. Olivier P, Boulbés O, Tubery M, Lauque D, Montastruc JL, Lapeyre-Mestre M. Assessing the feasibility of using an adverse drug reaction preventability scale in clinical practice: a study in a French emergency department. Drug Saf. 2002;25(14):1035–44.
6. Desai RJ, Williams CE, Greene SB, Pierson S, Caprio AJ, Hansen RA. Analgesic medication errors in North Carolina nursing homes. J Pain Palliat Care Pharmacother. 2013;27(2):125–31.
7. Rajanayagam J, Bishop JR, Lewindon PJ, Evans HM. Paracetamol-associated acute liver failure in Australian and New Zealand children: high rate of medication errors. Arch Dis Child. doi:10.1136/archdischild-2013-304902. (Epub 2014 Sep 16).
8. Ferner RE, Aronson JK. Preventability of drug-related harms—part I: a systematic review. Drug Saf. 2010;33(11):985–94.
9. Aronson JK, Ferner RE. Preventability of drug-related harms—part II: proposed criteria, based on frameworks that classify adverse drug reactions. Drug Saf. 2010;33(11):995–1002.
10. Uppsala Monitoring Centre. Monitoring medicines. 2014. www.monitoringmedicines.org. Accessed 16 Mar 2014.
11. Benabdallah G, Benkirane R, Khattabi A, Edwards IR, Soulaymani Bencheikh R. The involvement of pharmacovigilance centres in medication errors detection: a questionnaire-based analysis. Int J Risk Saf Med. 2011;23(1):17–29.
12. UMC presents ‘ICSRs and VigiBase—the vital importance of quality’. 9 March 2012. http://www.who-umc.org/DynPage.aspx?id=108464&mn1=7347&mn2=7489&mn3=7248&newsid=10762. Accessed 30 Nov 2012.
13. Morimoto T, Gandhi TK, Seger AC, Hsieh TC, Bates DW. Adverse drug events and medication errors: detection and classification methods. Qual Saf Health Care. 2004;13:306–14.
14. Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment. http://www.who-umc.org/Graphics/24734.pdf. Accessed 20 Jan 2013.
15. Uppsala Monitoring Centre. WHO-ART—WHO adverse reaction terminology. http://www.umc-products.com/DynPage.aspx?id=73589&mn1=1107&mn2=1664. Accessed 10 Jan 2012.
16. MedDRA. Medical dictionary for regulatory activities. http://www.meddra.org. Accessed 10 Jan 2012.
17. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–74.
18. Kunac DL, Reith DM, Kennedy J, Austin NC, Williams SM. Inter- and intra-rater reliability for classification of medication related events in paediatric inpatients. Qual Saf Health Care. 2006;15:196–201.
19. Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992;27:538.
20. Imbs JL, Pletan Y, Spriet A, et al. Evaluation de la iatrogénèse médicamenteuse évitable: méthodologie. Therapie. 1998;53:365–70.
21. Hakkarainen KM, Andersson Sundell K, Petzold M, Hägg S. Methods for assessing the preventability of adverse drug events: a systematic review. Drug Saf. 2012;35(2):105–26.
22. Zegers M, de Bruijne MC, Wagner C, et al. The inter-rater agreement of retrospective assessments of adverse events does not improve with two reviewers per patient record. J Clin Epidemiol. 2010;63(1):94–102.
23. World Health Organization. Reporting and learning systems for medication errors: the role of pharmacovigilance centres. 2014. http://apps.who.int/iris/bitstream/10665/137036/1/9789241507943_eng.pdf?ua=1. Accessed 28 Nov 2014.
24. Lip GY, et al. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace. 2011;13:723–46.
25. Ibanez L, Vidal X, Ballarin E, Laporte JR. Population-based drug-induced agranulocytosis. Arch Intern Med. 2005;165(8):869–74.
26. Andrade SE, Martinez C, Walker AM. Comparative safety evaluation of non-narcotic analgesics. J Clin Epidemiol. 1998;51(12):1357–65.